• On track to meet regional break-even guidance by end of FY26
• Q1 core test volumes up 145% vs PCP, annualised run rate surpassed 20,000 tests
• Continued strong growth in Australia and UK markets

Microba Life Sciences Limited (ASX: MAP) has reported a strong Q1 FY26, with key highlights including being on track to meet regional break-even guidance by the end of FY26, Q1 core test volumes up 145% versus the prior corresponding period (PCP), and an annualised run rate surpassing 20,000 tests. In Australia, the company saw record Q1 MetaXplore test sales of 3,884, up 112% versus PCP, and a Q1 MetaXplore annualised run-rate of 15,500+ tests sold, up 112% versus PCP. In the United Kingdom, Microba continued to see strong growth in MetaXplore test sales, with record Q1 MetaXplore test sales of 783, up 83% quarter-on-quarter. Q1 FY26 total revenue was $3.6 million, down 1% versus PCP, but excluding legacy product revenue, growth product revenue grew 42% versus PCP. The company maintained a strong focus on cost discipline, achieving a 26% reduction in underlying operating expenditure in Q1 FY26 versus Q4 FY25, excluding one-off and restructuring costs. Microba held $13.89 million in cash or equivalents at 30 September 2025 and expects to receive approximately $3 million under the FY25 R&D Tax Incentive before the end of Q2 FY26.

Microba is on track to meet its regional break-even guidance by the end of FY26.

Microba remains focused on continuing to accelerate sales of its core Growth testing products across Australia and the United Kingdom, and expects sales to build across each quarter of the financial year aligned to growth in clinician adoption and higher usage per clinician aligned to planned key product feature releases.